Completed
Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®
NCT06587451· Phase 3· H e x a l AG· Source
Completed
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermatitis.
NCT06447506· Phase 2· Glaxosmithkline Research & Development Limited· Source
Completed
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source
Completed
A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome
2023-503923-24-00· Phase 3· Horizon Therapeutics Ireland Designated Activity Company· Source
Completed
Testing a New Medication (Etrinabdiona) for Leg Circulation disease: A Study of Safety, Tolerability and Preliminary Efficacy
2023-509452-34-00· Phase 2· Vivacell Biotechnology Espana S.L.· Source
Completed
A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1
NCT05870748· Phase 2· Sutro Biopharma Inc.· Source
Terminated
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573· Phase 2/3· Boehringer Ingelheim· Source
Completed
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
NCT06350123· Phase 2· AstraZeneca· Source
Completed
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source
Active, not recruiting
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326· Phase 3· Pfizer· Source
Completed
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)
NCT05996835· Phase 2· Novartis Pharmaceuticals· Source
Completed
A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer
2023-503356-27-00· Phase 2· Inspirna Inc.· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
2023-505816-39-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2-positive non-resectable locally advanced or metastatic breast cancer “TrasTUCAN Study”
NCT05583110· Phase 1/2· Fundacion Grupo Espanol De Investigacion En Cancer De Mama· Source
Completed
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG)
2024-512258-91-00· Phase 3· Immunovant Sciences GmbH· Source
Completed
Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities
NCT05549180· Phase 4· Fundacion SEIMC-GESIDA· Source
Completed
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182· Phase 3· Janssen Research & Development, LLC· Source
Completed
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
NCT04991935· Phase 3· Celgene· Source
Completed
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
NCT05452239· Phase 4· H. Lundbeck A/S· Source
Completed
Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT05097989· Phase 2· Alexion Pharmaceuticals Inc.· Source
Completed
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia.
2021-002192-19· Phase 3· Ionis Pharmaceuticals Inc.· Source
Completed
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358· Phase 2· GlaxoSmithKline· Source
Terminated
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366· Phase 3· ModernaTX, Inc.· Source
Completed
Study to assess the efficacy and safety of alpelisib in combination with olaparib in participants with platinum-resistant or refractory gBRCAnm HGSOC
NCT04729387· Phase 3· Novartis Pharma AG· Source
Completed
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients with Homozygous and Heterozygous Familial Hypercholesterolemia, Cardiovascular Disease, or at High Risk for Cardiovascular Disease.
NCT04798430· Phase 3· Lib Therapeutics LLC· Source
Completed
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· Phase 3· Novo Nordisk A/S· Source
Completed
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616· Phase 2· UCB Biopharma SRL· Source
Completed
Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine
NCT04921384· Phase 3· H. Lundbeck A/S· Source
Active, not recruiting
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
NCT04486378· Phase 2· BioNTech SE· Source
Active, not recruiting
Myasthenia Gravis Inebilizumab Trial
NCT04524273· Phase 3· Amgen· Source
Completed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544· Phase 3· Sun Pharmaceutical Industries Limited· Source
Completed
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
NCT04436640· Phase 3· UCB Biopharma SRL· Source
Completed
An efficacy and safety study of 2-OHOA in patients with glioblastoma
2024-511542-39-00· Phase 2/3· Laminar Pharmaceuticals S.A.· Source
Completed
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
NCT04009499· Phase 3· UCB Biopharma SRL· Source
Completed
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
NCT04036435· Phase 3· Bristol-Myers Squibb· Source
Completed
Long-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457· Phase 3· Pfizer· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
"Safety, efficacy, immunogenicity study of GSK Biologicals’ HBV viral vector and adjuvanted proteins vaccine (GSK3528869A) in adult patients with chronic Hepatitis B infection.
"
NCT03866187· Phase 1/2· GlaxoSmithKline Biologicals· Source
Active, not recruiting
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957· Phase 3· AstraZeneca· Source
Completed
A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation
2023-508726-10-00· Phase 3· Bristol-Myers Squibb Services Unlimited Company· Source
Completed
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT03422822· Phase 3· Pfizer· Source
Active, not recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· Phase 3· Tesaro, Inc.· Source
Completed
A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer.
NCT02743494· Phase 3· Bristol Myers Squibb International Corporation· Source
Active, not recruiting
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318· Phase 3· Aragon Pharmaceuticals, Inc.· Source
Completed
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT02486718· Phase 3· Hoffmann-La Roche· Source